Ibuspray
Product Summary
1. NAME OF THE MEDICINAL PRODUCT IBUSPRAY
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Ibuprofen 5.0% w/w
3. PHARMACEUTICAL FORM
Cuntaneous spray solution.
Clear, colourless, fragrance-free, aqueous-alcoholic topical spray
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
For the topical treatment of backache, rheumatic and muscular pain, sprains, strains and neuralgia. Ibuspray is also indicated for symptomatic relief of pain due to non-serious arthritic conditions.
4.2 Posology and method of administration
Hold the bottle upright or upside down and spray approximately 4 inches to 6 inches away from the skin. After every 2 to 3 sprays, gently massage the preparation into the skin, spreading the product over a wide area around the affected site. The exact amount to be applied will vary, depending on the extent and severity of the condition, but it should normally be sufficient to apply 5 to 10 sprays (1 to 2 ml). This amount may be repeated three to four times daily, or more often if required. Do not use excessively.
Hands should be washed after use, unless treating them.
Treatment should not normally continue for more than a few weeks, unless recommended to do so by a doctor.
The same dosage and dosage schedule applies to all age groups, although Ibuspray is not normally recommended for use on children below the age of 12 years unless instructed by their doctor.
4.3 Contraindications
Not to be used in cases of sensitivity to any of the ingredients, particularly if asthmatic or suffer from rhinitis or urticaria, and have previously shown hypersensitivity to aspirin or ibuprofen or related painkillers.
Not to be used on broken skin.
4.4 Special warnings and precautions for use
This product is flammable. Do not spray near flames, electric heaters or similar objects.
Seek medical advice if symptoms worsen or persist.
Oral NSAIDs, including ibuprofen, can sometimes be associated with renal impairment, aggravation of active peptic ulcers, and can induce allergic bronchial reactions in susceptible asthmatic patients. Although the systemic absorption of topically applied ibuprofen is much less than from oral dosage forms, these complications can occur in rare cases. For these reasons, patients with an active peptic ulcer, a history of kidney problems, asthma or intolerance to aspirin or ibuprofen should seek medical advice before using Ibuspray.
Keep away from the eyes and mucous membranes.
For external use only.
The label will include statements to the following effect:
If symptoms persist, consult your doctor or pharmacist.
Do not use if sensitive to any of the ingredients, particularly if asthmatic, suffer from rhinitis or urticaria and have previously shown hypersensitivity to aspirin, ibuprofen or related painkillers.
Consult your doctor before use if you are taking aspirin or other painkillers.
4.5 Interaction with other medicinal products and other forms of interaction
Non-steroidal anti-inflammatory drugs may interact with blood pressure lowering drugs, and may possibly enhance the effects of anticoagulants, although the chance of this either of these occurring with a topically administered preparation is extremely remote. Concurrent aspirin or other NSAIDs may result in an increased incidence of undesirable effects.
4.6 Pregnancy and lactation
Do not use during pregnancy or lactation.
4.7 Effects on ability to drive and use machines
None known
4.8 Undesirable effects
Very rarely, susceptible patients may experience the following side effects with ibuprofen, but these are extremely uncommon when ibuprofen is administered topically. If they occur, treatment should be discontinued:-Hypersensitivity: hypersensitivity reactions have been reported following treatment with ibuprofen. These may consist of (a) non-specific allergic reactions and anaphylaxis, (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm, or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angioedema and, less commonly, bullous dermatoses (including epidermal necrolysis and erythema multiforme).
Renal: renal impairment can occur in patients with a history of kidney problems.
Gastrointestinal: side effects such as abdominal pain and dyspepsia have been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Not applicable. Any overdose with a topical presentation of ibuprofen is unlikely.
PHARMACOLOGICAL PROPERTIES
5.
5.1 Pharmacodynamic Properties
Ibuspray is a topical preparation which has anti-inflammatory and analgesic properties. It contains the active ingredient, ibuprofen, which exerts its effects directly in inflamed tissues underlying the site of application, mainly by inhibiting prostaglandin biosynthesis.
Because it is formulated in an evaporative aqueous/alcoholic solution, Ibuspray also exerts a soothing and cooling effect when applied to the affected area.
5.2 Pharmacokinetic properties
Specially formulated for external application, the active ingredient penetrates through the skin rapidly and extensively, achieving high, therapeutically relevant local concentrations in underlying soft tissues, joints and synovial fluid, whilst producing plasma levels that are unlikely to be sufficient to cause any systemic side effects, other than in rare individuals who are hypersensitive to ibuprofen.
Furthermore, there do not appear to be any appreciable differences between the oral and topical routes of administration regarding metabolism or excretion of ibuprofen.
5.3 Preclinical safety data
No relevant information additional to that contained elsewhere in the SPC.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
IMS
Macrogol 300
Macrogol cetostearyl ether (cetomacrogol) Purified Water
6.2 Incompatibilities
None known
6.3 Shelf life
36 months.
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
High density polyethylene cylindrical BOTTLES incorporating a controlled dose
SPRAY PUMP dispenser and OVERCAP (containing 35, 100 or 120 ml of product).
Supplied as original packs.
6.6 Instruction for use and handling
Not applicable
Administrative Data
7. MARKETING AUTHORISATION HOLDER
Diomed Developments Limited T/A Dermal Laboratories Tatmore Place, Gosmore Hitchin, Herts SG4 7QR, UK
8. MARKETING AUTHORISATION NUMBER
PL 00173/0150
9. DATE OF FIRST AUTHORISATION/RENEWAL OF
AUTHORISATION
23 September 1993
10
DATE OF REVISION OF THE TEXT
14/07/2015